欢迎来到《四川大学学报(医学版)》 2025年3月31日 星期一

43例IgG4相关性疾病患者临床诊治分析

张杰, 岑筱敏, 赵华, 杨闵, 刘毅, 谢其冰

张杰, 岑筱敏, 赵华, 等. 43例IgG4相关性疾病患者临床诊治分析[J]. 四川大学学报(医学版), 2020, 51(5): 714-719. DOI: 10.12182/20200960604
引用本文: 张杰, 岑筱敏, 赵华, 等. 43例IgG4相关性疾病患者临床诊治分析[J]. 四川大学学报(医学版), 2020, 51(5): 714-719. DOI: 10.12182/20200960604
ZHANG Jie, CEN Xiao-min, ZHAO Hua, et al. Diagnosis and Treatment of 43 Patients with IgG4-related Disease[J]. Journal of Sichuan University (Medical Sciences), 2020, 51(5): 714-719. DOI: 10.12182/20200960604
Citation: ZHANG Jie, CEN Xiao-min, ZHAO Hua, et al. Diagnosis and Treatment of 43 Patients with IgG4-related Disease[J]. Journal of Sichuan University (Medical Sciences), 2020, 51(5): 714-719. DOI: 10.12182/20200960604

栏目: 临床医学

43例IgG4相关性疾病患者临床诊治分析

基金项目: 四川大学华西医院学科卓越发展1•3•5工程项目(No. ZYGD18015)资助
详细信息
    通讯作者:

    谢其冰: E-mail:xieqibing1971@163.com

Diagnosis and Treatment of 43 Patients with IgG4-related Disease

More Information
  • 摘要:
      目的  分析总结IgG4相关性疾病(IgG4-related disease, IgG4-RD)患者临床、病理特征及诊治经验。
      方法  回顾性分析2013年1月−2017年12月四川大学华西医院收治的43例IgG4-RD患者的临床资料(包括临床表现、实验室检查、影像学及病理学检查,诊断、误诊及治疗情况)。
      结果  43例IgG4-RD患者中,男女性别比为3∶1,年龄(51.3±15.9)岁,临床表现为腹痛、黄疸、乏力等消化道症状者11例(IgG4相关性胆管炎5例,IgG4相关性自身免疫性胰腺炎6例),占25.6%;眶周受累患者10例,占23.3%,淋巴结肿大患者9例,占20.9%,发热患者6例,占14.0%;42例患者行免疫自身抗体检查,抗核抗体(ANA)升高14例;40例患者行免疫球蛋白检查,IgG升高25例,IgA升高12例,IgE升高29例;6例患者行直接抗人球蛋白实验,4例为阳性;血清免疫球蛋白G4亚型检测显示,35例患者高于1 350 mg/L;影像学检查显示,眶周受累患者CT特征为眼眶内软组织结节;胆道及胰腺受累患者腹部增强CT扫描特征为肝内胆管扩张、胆总管扩张,管壁增厚强化,管腔变窄,胰腺受累显示胰腺肿大或软组织密度影;组织病理学检查免疫组化染色表现为IgG4阳性细胞(3~>500个/高倍视野)浸润,淋巴细胞CD20、CD3ε或浆细胞CD138阳性。43例患者中5例因误诊行手术治疗。所有患者确诊后采用激素及免疫抑制剂等药物治疗,临床症状均好转。
      结论  IgG4-RD临床表现多样,累及多器官,临床上应加强对IgG4-RD的规范诊断和治疗。

     

    Abstract:
      Objective   To summarize the clinicopathological characteristics, diagnosis and treatment of IgG4-related disease (IgG4-RD).
      Methods  The clinical data of 43 cases with IgG4-RD diagnosed from January 2013 to December 2017 were retrospectively analyzed. The clinical data of the patients including clinical characteristics, accessory examinations, diagnosis, and treatment were collected.
      Results  Among the 43 patients with IgG4-RD, the ratio of male to female was 3∶1, the mean age was (51.3±15.9) years. Eleven patients had gastrointestinal symptoms, including 5 cases of IgG4-related cholangitis with the feature of dilation of the biliary system and narrowing of the lumen in the abdominal enhanced CT scans, and 6 cases of IgG4-related autoimmune pancreatitis with the feature of pancreatic enlargement or soft tissue density shadow in the abdominal enhanced CT scans. There were 10 cases (23.3%) with periorbital involvement, with the feature of intraorbital soft tissue nodule in the CT scan. Besides, 9 cases (20.9%) had lymphadenopathy, 6 cases (14.0%) had fever. The results of autoimmune antibody tests showed that 14 of 42 patients had increased antinuclear antibody (ANA). Among 40 patients who underwent immunoglobulin tests, 25 cases had elevated IgG, 12 cases had increased IgA, and 29 cases had increased IgE. Coombs test were performed for 6 cases and 4 patients were positive. Serum immunoglobulin G4 subtypes showed that the IgG4 levels of 35 patients were higher than 1 350 mg/L. The immunohistochemistry showed that IgG4 (+) cells (3->500/HPF) were infiltrated, with the CD20 (+), CD3ε (+) or CD138 (+). Among the 43 patients, 5 patients underwent operations due to misdiagnosis. All patients were treated with steroid and immunosuppressive agents after diagnosis, and their clinical symptoms were improved.
      Conclusion  The clinical symptoms of IgG4-RD are various, involving multiple organs. Therefore, the standardized diagnosis and treatment of IgG4-RD should be strengthened.

     

  • IgG4相关性疾病(IgG4-related disease, IgG4-RD)是一种与IgG4相关、累及多器官与组织的慢性炎症性、纤维化性、进行性的自身免疫性疾病,通常以单个或多个器官肿大起病,伴或不伴血清IgG4增高[1]。目前我国很多医务人员对该疾病的认识存在不足,导致部分患者未得到及时的正确诊断和治疗,为此,本研究对2013−2017年在四川大学华西医院诊治的43例IgG4-RD患者的临床资料进行分析总结,以期提高临床医务人员对该疾病的认识,从而减少对该疾病的漏诊、误诊,为临床诊断和治疗提供经验。

    纳入2013年1月−2017年12月于四川大学华西医院诊治的43例IgG4-RD 患者为研究对象。所有患者诊断参照2012年日本IgG4-RD综合分类诊断标准[2]。43例患者中男性32例,女性11例,男女比例为3∶1,年龄(51.3±15.9)岁,病程(1.83±3.6)年。本研究获得四川大学华西医院伦理委员会批准(2019-497号),所有患者均知情同意。

    常规进行血常规、血生化、血沉(erythrocyte sedimentation rate, ESR)、C反应蛋白(C-reactive protein, CRP)、肿瘤标志物等检查,免疫学检查包括抗核抗体(antinuclear antibody, ANA)、可提取的核抗原(extractable nuclear antigen, ENA)抗体谱、抗中性粒细胞胞浆抗体(antineutrophil cytoplasmic antibody, ANCA)、免疫球蛋白IgG、IgA、IgE(正常参考范围IgG为8.00~15.50 g/L、IgA为836~2 900 mg/L、IgE为0.1~150.0 IU/mL)、补体C3、C4(正常参考范围分别为0.785~1.520 g/L、0.145~0.360 g/L)。影像学检查包括CT(17例)、MRI(7例)、PET-CT(4例);37例患者行组织病理学检查(包括组织病理切片进行HE染色及免疫组化染色)。

    本组43例IgG4-RD患者中临床表现为腹痛、黄疸、乏力等消化道症状者11例(占25.6%),其中IgG4相关性胆管炎5例,IgG4相关性自身免疫性胰腺炎6例;眶周受累患者10例(占23.3%);淋巴结肿大患者9例(占20.9%);发热患者6例(占14.0%);其余7例(共占16.3%),包括腮腺肿胀患者2例(占4.7%),以咳嗽、呼吸困难为临床表现的浆膜腔积液患者2例(占4.7%),以声嘶、发现声门下气管狭窄起病1例(占2.3%),累及牙龈患者1例(占2.3%),肾脏损害患者1例(占2.3%)。

    血常规检查发现43例患者中8例为中度贫血(血红蛋白70~87 g/L)、12例为轻度贫血(血红蛋白95~111 g/L),其余患者血常规检查未发现异常。11例患者丙氨酸转氨酶及天门冬氨酸氨基转移酶增高。42例患者行免疫自身抗体检查,ANA升高14例,其中滴度1∶100为11例,滴度1∶320为3例,ENA 检查均为阴性,23例患者ANCA检查均为阴性。40例患者行免疫球蛋白检查,IgG升高25例,IgA升高12例,IgE升高29例,6例患者行直接抗人球蛋白(Coombs)实验,4例为阳性。见表1。40例患者行血清免疫球蛋白G4亚型检测,其中35例高于1 350 mg/L,平均为(16.8±27.9)g/L。

    表  1  43例IgG4-RD患者实验室检查结果
    Table  1.  The laboratory examination results of 43 IgG4-RD patients
    VariablenCase (%)
    IgG4>1 350 mg/L4035 (87.5)
    Hb<115 g/L4320 (46.5)
    ALT>50 IU/L4311 (25.6)
    AST>40 IU/L4311 (25.6)
    ANA≥1∶1004214 (33.3)
    ANCA (+)230 (0.0)
    C3↓3616 (44.4)
    C4↓3614 (38.9)
    IgG↑4025 (62.5)
    IgA↑4012 (30.0)
    IgE↑4029 (72.5)
    Coombs (+)64 (66.7)
     Hb: Hemoglobin; ALT: Alanine transaminase; AST: Aspartate amino transferase; ANA: Antinuclear antibody; ANCA: Antineutrophil cytoplasmic antibody.
    下载: 导出CSV 
    | 显示表格

    7例眶周受累患者行双眼轴位+冠状位CT扫描,4例患者显示眼眶内出现软组织结节(图1),3例显示有眼外肌增粗,1例显示泪腺肿大,3例显示眼睑软组织肿胀,2例显示眼球突出。7例患者眼球内结构、密度、视神经均未见受累。

    图  1  IgG4-RD双眼CT扫描结果
    Figure  1.  The result of CT scans of binoculus in the patients with IgG4-RD disease
    Soft tissue mass shadow (red arrow) can be seen between superior rectus and external in rectusbilateral lacrimal gland area.

    胆道及胰腺受累患者中,9例行腹部增强CT扫描,1例患者显示胆管及胰腺同时受累,5例提示胆管受累,包括肝内胆管扩张、胆总管扩张,管壁增厚强化,管腔变窄,其中3例显示肝内肝管扩张。5例提示胰腺受累,其中3例显示胰腺轻度肿大,1例显示胰腺普遍增大,1例显示胰腺体尾部见一大小约4.0 cm×8.7 cm软组织密度影(图2),边界不清,5例胰腺受累患者均未显示胰管扩张。

    图  2  IgG4相关性自身免疫性胰腺炎患者上腹部CT扫描结果
    Figure  2.  The results of CT scan of upper abdomen in the patients with IgG4-related autoimmune pancreatitis
    A: 4.0 cm×8.7 cm density reduction (red arrow) shadow with unclear boundary can be seen at the tail of pancreas; B: The degree of enhancement of density (red arrow) shadow in arterial phase was significantly lower than adjacent normal pancreatic parenchyma.

    1例气管狭窄患者颈部增强CT显示上段气管管腔变窄,管腔周边软组织密度影环绕。

    7例行上腹部MRI增强扫描,6例显示胆管受累,其中5例显示肝内外胆管扩张,1例显示胆总管胰头段管壁增厚,管腔明显狭窄,1例显示肝门区胆管壁增厚,局部胆管中断,此2例诊断考虑为胆管肿瘤。2例显示胰腺受累,其中1例显示胆管及胰腺同时受累,表现为肝内外胆管壁增厚、胰腺体积明显增大。

    4例患者行PET-CT检查,其中2例为淋巴结肿大患者,PET-CT显示全身多个淋巴结代谢增高,1例为牙龈增生患者,PET-CT显示颌下腺、腮腺、牙槽周围及胰腺糖代谢增高,1例为上眼睑、下颌包块患者,PET-CT显示泪腺、唾液腺、胰腺、全身淋巴结糖代谢增高。

    共有37例患者行组织病理学检查,其中32例患者组织行免疫组化染色检查,病检部位包括骨髓、淋巴结、眼眶肿物、胰腺、胆管、胸膜、腮腺、皮肤、肾脏及鼻腔组织。免疫组化染色示19例患者淋巴细胞CD20(+),14例患者淋巴细胞CD3ε(+),22例患者浆细胞CD138(+)。

    13例患者行骨髓穿刺检查,其中7例骨髓受累,免疫组化染色示IgG4〔+,3~50个/高倍视野(HPF)〕,6例示浆细胞CD138(+),4例示淋巴细胞CD3ε(+),CD20(+);9例患者行淋巴结活检,免疫组化示IgG4(+,10~>300个/HPF),其中8例示浆细胞CD138(+),6例示淋巴细胞CD20(+),4例示淋巴细胞CD3ε(+);5例患者行眼眶肿物活检,免疫组化示IgG4(+,50~>500个/HPF),其中4例示浆细胞CD138(+),4例示淋巴细胞CD20(+),2例示淋巴细胞CD3ε(+);2例患者行胰腺病理检查,示较多淋巴细胞、浆细胞聚集浸润,其中1例示间质广泛纤维组织增生,玻璃样变,免疫组化示IgG4阳性细胞约30~70个/HPF;2例行肝内胆管病理检查,1例示慢性胆管炎伴胆管周围炎,局部肉芽组织增生及小胆管增生,1例示胆管壁大量淋巴细胞、浆细胞浸润,间质纤维化,免疫组化示IgG4(+,180个/HPF),免疫组化示CD20(+)、CD3p(+)、CD138(+);2例患者行胸膜活检,免疫组化示IgG4(+,80~>100个/HPF),均示淋巴细胞CD20(+),1例示浆细胞CD138(+),1例示淋巴细胞CD3ε(+),1例示淋巴细胞CD3p(+);2例患者行腮腺活检,其中1例免疫组化示IgG4(+,>100个/HPF),淋巴细胞CD20(+),浆细胞CD138(+);1例患者行皮肤活检,免疫组化示CD138(+),IgG4(±);1例患者行肾穿刺活检,示肾小管间质重度损伤,肾小球广泛球性硬化,免疫组化示IgG4(+,约10~15个/HPF);1例行鼻腔组织病理检查,免疫组色示IgG4(部分+,分布不均匀,灶区达30个/HPF),CD20(+)、CD3ε(+),浆细胞CD138(+)。见表2图3

    表  2  各组织免疫组化染色IgG4阳性细胞数及CD20、CD138、CD3ε阳性表达结果
    Table  2.  The number of IgG4 positive cells and positive the expression of CD20, CD138 and CD3 ε in pathological immunohistochemistry
    VariablenIgG4+/HPFCD20+/case (%)CD138+/case (%)CD3ε+/case (%)
    Bone marrow133-504 (30.8)6 (46.2)4 (30.8)
    Lymph node910->3008 (88.9)6 (66.7)4 (44.4)
    Periorbital mass550->5004 (80.0)4 (80.0)2 (40.0)
    Pancreas, bile duct430-1801 (25.0)1 (25.0)0 (0.0)
    Pleura280->1002 (100.0)1 (50.0)1 (50.0)
    Parotid gland2>1001 (50.0)1 (50.0)0 (0.0)
    Skin1±0 (0.0)1 (100.0)0 (0.0)
    Nephridial tissue110-150 (0.0)0 (0.0)0 (0.0)
    Nasal tissue1301 (100.0)1 (100.0)1 (100.0)
    HPF:High power field.
    下载: 导出CSV 
    | 显示表格
    图  3  IgG4+浆细胞、CD20、CD138、CD3ε在IgG4-RD各病理组织IHC染色及胰腺病理组织HE染色。 ×200
    Figure  3.  IHC staining of IgG4-RD with the IgG4+ plasma cells, CD20, CD138, CD3ε and HE staining of the pancreas tissue. ×200
    A: IHC staining of periorbital mass with the IgG4+ plasma cells; B: IHC staining of lymph node with the CD20+; C: IHC staining of periorbital mass with the CD138+; D: IHC staining of bone marrow with the CD3ε+; E: HE staining of proliferation of fibrous tissue of pancreas, a large number of lymphocytes and plasma cells infiltrated.

    11例IgG4相关性胆管炎及自身免疫性胰腺炎患者中,5例患者因误诊行手术治疗,2例行肝门胆管癌根治术+肝门部胆管成形术+门静脉修复术+下腔静脉缝合术,1例行胰十二指肠切除术+门静脉修补+肝门成形术+空肠造瘘术+胆囊摘除术,1例行胰体部占位切除术,1例行脾切除+胰腺穿刺活检,5例均行病理学检查,其中4例行病理免疫组化检查,获得病理学依据。临床表现为发热及淋巴结肿大的15例患者中,9例因考虑感染予以抗感染治疗。

    所有患者于明确诊断后均予以激素治疗,剂量为泼尼松每天40~60 mg,10例患者加用环磷酰胺治疗,其中5例患者为每月环磷酰胺1 000 mg冲击治疗,5例患者为每日环磷酰胺50 mg口服治疗,6例患者加用吗替麦考酚酯治疗,4例患者加用甲氨蝶呤治疗,经治疗后患者临床症状均好转。

    IgG4-RD为本世纪才被认识并命名的一种疾病,可累及全身各组织器官,出现多种临床表现,经常影响胰腺、唾液腺和淋巴结,非常容易复发[3],部分患者血清IgG4增高及以IgG4阳性浆细胞在组织浸润为其特点,但血清IgG4浓度不能作为IgG4-RD的诊断标志物、判断疾病活动及对治疗反应的指标,大约20%~40%经活检证实的IgG4-RD患者血清IgG4浓度正常[4]。MASAKI等[5]研究发现,血清IgG4>135 mg/dL在诊断IgG4-RD时的敏感性和特异性分别为97.0%和79.6%,血清IgG4/IgG比例>8%时诊断IgG4-RD的敏感性和特异性分别为95.5%和87.5%,组织中IgG4+细胞/IgG+细胞比例>40%时诊断IgG4-RD的敏感性和特异性分别为94.4%和85.7%,然而,在严重纤维化的组织部分IgG4+细胞的数量会减少。

    本研究中43例患者发病年龄(51.3±15.9)岁,男女比例为3∶1,累及器官为胰腺、胆管、泪腺、淋巴结等,与文献报道[6]基本一致。

    IgG4-RD患者较大比例会出现ANA和类风湿因子阳性,但通常血清滴度很低,进行ANA和其他自身抗体的检测在鉴别诊断方面非常重要。一些风湿性疾病可能有IgG4-RD样表现[7-8]。本研究43例患者中,ANA阳性14例,11例滴度为1∶100(+),3例滴度为1∶320(+),与文献报道一致。6例行直接抗人球蛋白实验的患者中,4例为阳性,其中2例为中度贫血,但原因尚不清楚,需行进一步的研究明确。

    CT、MRI等影像学检查在IgG4-RD的鉴别诊断和判断疾病程度方面非常重要,但CT、MRI等检查并没有特征性的表现[6]。本研究中,7例患者行上腹部增强MRI检查,2例影像学诊断均考虑胆管肿瘤,5例患者因误诊行手术治疗,由于自身免疫性胰腺炎影像学表现多样,表现为弥漫性或局限性胰腺增大伴延迟增强,部分可见包囊样边缘影,特别是局限性增大者,与胰腺癌或胆管癌的鉴别诊断尤为困难[9],使许多患者经受了不必要的手术治疗,对于影像学检查表现为胆管、胰腺等受累的患者,应行血清IgG4等相关检查,避免误诊。(FDG PET)/CT检查可以突出活动性炎症性病变和判断疾病程度,因此可能作为IgG4-RD有效的诊断方法,但在与恶性肿瘤鉴别方面,也仍难以鉴别[6]。ZHANG等[10]通过对35例IgG4-RD患者的(FDG PET)/CT研究发现,所有35例患者均发现高代谢病变,97.1%的患者表现为多器官受累,71.4%的患者(FDG PET)/CT检查显示比超声、CT等检查更多的器官受累,(FDG PET)/CT是评估器官受累、监测治疗反应和指导介入治疗的有效方法。

    IgG4-RD通常对大剂量糖皮质激素治疗有效,初始平均剂量为40 mg/d,然后在3~6个月内逐渐减量,KARIM等[11]报道英夫利昔单抗可以作为对激素治疗效果不佳的IgG4-RD患者的另一选择。抗CD20单抗(利妥昔单抗,Rituximab)是一种人鼠嵌合性单克隆抗体,能特异性地与跨膜抗原CD20结合,有效清除B细胞,常用于治疗CD20阳性B细胞淋巴瘤。多项研究证实利妥昔单抗可以作为诱导或维持治疗方案[12-13],并建议作为二线治疗方案[3]。本研究也发现,37例行病理学检查的IgG4-RD患者中,免疫组化示19例患者淋巴细胞CD20(+),淋巴结、眼眶肿物活检免疫组化CD20阳性比例较高,提示CD20可能参与了IgG4-RD的发病过程,为利妥昔单抗治疗IgG4-RD提供了病理学依据,利妥昔单抗可能对CD20阳性的IgG4-RD患者具有较好的临床疗效,但有待于进一步研究。14例患者淋巴细胞CD3ε(+),22例患者浆细胞CD138(+),淋巴细胞CD3ε、CD138等可能作为潜在的治疗靶点。

    目前,临床上尚缺乏评估IgG4-RD疾病活动度的有效血清学标志物。AKIYAMA等[14]研究发现,CC亚族趋化因子18(CCL18)可以作为评估IgG4-RD疾病活动度的生物标记物。WALLACE等[15]通过流式细胞学对经活检证实但未治疗的病情活跃IgG4-RD患者循环浆细胞及IgG4阳性浆细胞的检测发现,循环浆细胞在病情活跃及血清IgG4浓度正常的IgG4-RD患者中升高,浆细胞计数可以作为诊断、评估治疗反应等的一种生物标志物。

    由于我国对IgG4-RD的认识和重视程度不够,也导致了很多误诊的发生。谢思明等[9]对13例自身免疫性胰腺炎的分析发现,13例中,8例误诊而行剖腹探查术。其中4例误诊为胰腺癌,3例行胰十二指肠切除术,1 例行胰体尾+脾切除术;1例误诊为胆总管下段癌而行胰十二指肠切除术;1例误诊为肝门胆管癌。因此,我们认为正确诊断IgG4-RD的关键在于充分认识其临床病理特点,细致及充分的实验室检查及影像学检查,且需风湿免疫科、肝胆外科、影像科、病理科等多学科医师的协作诊治。

  • 图  1   IgG4-RD双眼CT扫描结果

    Figure  1.   The result of CT scans of binoculus in the patients with IgG4-RD disease

    Soft tissue mass shadow (red arrow) can be seen between superior rectus and external in rectusbilateral lacrimal gland area.

    图  2   IgG4相关性自身免疫性胰腺炎患者上腹部CT扫描结果

    Figure  2.   The results of CT scan of upper abdomen in the patients with IgG4-related autoimmune pancreatitis

    A: 4.0 cm×8.7 cm density reduction (red arrow) shadow with unclear boundary can be seen at the tail of pancreas; B: The degree of enhancement of density (red arrow) shadow in arterial phase was significantly lower than adjacent normal pancreatic parenchyma.

    图  3   IgG4+浆细胞、CD20、CD138、CD3ε在IgG4-RD各病理组织IHC染色及胰腺病理组织HE染色。 ×200

    Figure  3.   IHC staining of IgG4-RD with the IgG4+ plasma cells, CD20, CD138, CD3ε and HE staining of the pancreas tissue. ×200

    A: IHC staining of periorbital mass with the IgG4+ plasma cells; B: IHC staining of lymph node with the CD20+; C: IHC staining of periorbital mass with the CD138+; D: IHC staining of bone marrow with the CD3ε+; E: HE staining of proliferation of fibrous tissue of pancreas, a large number of lymphocytes and plasma cells infiltrated.

    表  1   43例IgG4-RD患者实验室检查结果

    Table  1   The laboratory examination results of 43 IgG4-RD patients

    VariablenCase (%)
    IgG4>1 350 mg/L4035 (87.5)
    Hb<115 g/L4320 (46.5)
    ALT>50 IU/L4311 (25.6)
    AST>40 IU/L4311 (25.6)
    ANA≥1∶1004214 (33.3)
    ANCA (+)230 (0.0)
    C3↓3616 (44.4)
    C4↓3614 (38.9)
    IgG↑4025 (62.5)
    IgA↑4012 (30.0)
    IgE↑4029 (72.5)
    Coombs (+)64 (66.7)
     Hb: Hemoglobin; ALT: Alanine transaminase; AST: Aspartate amino transferase; ANA: Antinuclear antibody; ANCA: Antineutrophil cytoplasmic antibody.
    下载: 导出CSV

    表  2   各组织免疫组化染色IgG4阳性细胞数及CD20、CD138、CD3ε阳性表达结果

    Table  2   The number of IgG4 positive cells and positive the expression of CD20, CD138 and CD3 ε in pathological immunohistochemistry

    VariablenIgG4+/HPFCD20+/case (%)CD138+/case (%)CD3ε+/case (%)
    Bone marrow133-504 (30.8)6 (46.2)4 (30.8)
    Lymph node910->3008 (88.9)6 (66.7)4 (44.4)
    Periorbital mass550->5004 (80.0)4 (80.0)2 (40.0)
    Pancreas, bile duct430-1801 (25.0)1 (25.0)0 (0.0)
    Pleura280->1002 (100.0)1 (50.0)1 (50.0)
    Parotid gland2>1001 (50.0)1 (50.0)0 (0.0)
    Skin1±0 (0.0)1 (100.0)0 (0.0)
    Nephridial tissue110-150 (0.0)0 (0.0)0 (0.0)
    Nasal tissue1301 (100.0)1 (100.0)1 (100.0)
    HPF:High power field.
    下载: 导出CSV
  • [1] 安乐美, 张卓莉. IgG4相关性疾病. 中华内科杂志,2013,52(8): 696–698. DOI: 10.3760/cma.j.issn.0578-1426.2013.08.027
    [2]

    UMEHARA H, OKAZAKI K, MASAKI Y, et al. Comprehensive diagnostic criteria for IgG4-relateddisease (IgG4-RD). Mod Rheumatol,2012,22(1): 21–30. DOI: 10.3109/s10165-011-0571-z

    [3]

    ARDILA-SUAREZ O, ABRIL A, JOSÉ A, et al. IgG4-related disease: a concise review of the current literature. Reumatol Clin,2017,13(3): 160–166. DOI: 10.1016/j.reuma.2016.05.009

    [4]

    STONE J H, KHOSROSHAHI A, DESHPANDE V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum,2014,64(10): 3061–3067. DOI: 10.1002/art.34593

    [5]

    MASAKI Y, KUROSE N, YAMAMOTO M ,et al. Cutoff values of serum IgG4 and histopathological IgG4+ plasma cells for diagnosis of patients with IgG4-related disease. Int J Rheumatol, 2012, 2012: 580814[2019-10-18]. https://doi.org/10.1155/2012/580814.

    [6]

    DAVID L, JOCHEN Z, HERWIG P. IgG4-related disease: current challenges and future prospects. Ther Clin Risk Managt,2016,12: 189–199.

    [7]

    STONE J H, BRITO-ZERÓN P, BOSCH X, et al. Diagnostic approach to the complexity of IgG4-related disease. Mayo Clin Proc,2015,90(7): 927–939. DOI: 10.1016/j.mayocp.2015.03.020

    [8]

    KIYAMA K, YOSHIFUJI H, KANDOU T, et al. Screening for IgG4-type antinuclear antibodies in IgG4-related disease. BMC Musculoskelet Disord, 2015, 16: 129[2019-10-18]. https://doi.org/10.1186/s12891-015-0584-4.

    [9] 谢思明, 程明亮, 陈拥华, 等. 自身免疫性胰腺炎13例临床诊治分析. 中华内分泌外科杂志,2014(6): 472–474. DOI: 10.3760/cma.j.issn.1674-6090.2014.06.010
    [10]

    ZHANG J, CHEN H, MA Y, et al. Characterizing IgG4-related disease with18F-FDG PET/CT: a prospective cohort study. Eur J Nucl Med Mol Imaging,2014,41(8): 1624–1634. DOI: 10.1007/s00259-014-2729-3

    [11]

    KARIM F, PARIDAENS D, WESTENBERG L E H, et al. Infliximab for IgG4-related orbital disease. Ophthalmic Plast Reconstr Surg, 2017, 33(3S Suppl 1): S162-S165[2019-10-18]. https://doi.org/10.1097/IOP.000000000000062.

    [12]

    BETANCUR-VASQUE L, GONZALEZ-HURTADO D, ARANGO-ISAZA D, et al. IgG4-related disease: is rituximab the best therapeutic strategy for cases refractory to conventional therapy? Results of a systematic review. Reumatol Clin,2020,16(3): 195–202. DOI: 10.1016/j.reuma.2018.11.011

    [13]

    CAMPOCHIARO C, DELLA-TORRE E, LANZILLOTTA M, et al. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. Eur J Intern Med,2020,74: 92–98. DOI: 10.1016/j.ejim.2019.12.029

    [14]

    AKIYAMA M, YASUOKA H, YOSHIMOTO K, et al. CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease. Ann Rheum Dis,2018,77(9): 1386–1387. DOI: 10.1136/annrheumdis-2017-212110

    [15]

    WALLACE Z S, MATTOO H, CARRUTHERS M, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis,2015,74(1): 190–195. DOI: 10.1136/annrheumdis-2014-205233

  • 期刊类型引用(3)

    1. 刘夏楠,吕亚平,高玉华,王雪玢,常谦,张世杰. IgG4相关性疾病患者临床特征和血清炎症免疫八项结果回顾性分析. 河南医学研究. 2024(07): 1211-1215 . 百度学术
    2. 李睿,李翔,周阳,朱树国. 血清IgG4临床分布特征及在IgG4相关性疾病诊断中的价值. 中国医学创新. 2024(22): 163-167 . 百度学术
    3. 冯月宁,韩志城,谢宇瑞,安阿玥. 血清IgG_4临床分布特征及在IgG_4相关性疾病诊断中的作用. 国际免疫学杂志. 2022(06): 583-588 . 百度学术

    其他类型引用(0)

图(3)  /  表(2)
计量
  • 文章访问数:  2837
  • HTML全文浏览量:  953
  • PDF下载量:  77
  • 被引次数: 3
出版历程
  • 收稿日期:  2019-10-01
  • 修回日期:  2020-01-11
  • 网络出版日期:  2020-09-20
  • 发布日期:  2020-09-19

目录

/

返回文章
返回